Reason for request
Extension of indication
Clinical Benefit
| Substantial |
The actual benefit of CERUBIDINE 20 mg is substantial, as part of a combination chemotherapy regimen, in the treatment of acute lymphoblastic leukaemia and acute myeloblastic leukaemia in children. |
Clinical Added Value
| no clinical added value |
CERUBIDINE 20 mg does not provide any improvement in actual benefit (level V, non-existent) in the treatment of acute lymphoblastic and myeloblastic leukaemia in children. |
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
nKRY3sNtJu69Q9NK
